Research Summary

I received the MD, PhD combined degree from Boston University and Urology residency training at UC Davis. I was recruited to join the UCSF faculty as Assistant Professor after completed the fellowship and trained as a urologic oncology surgeon under Dr. Peter Carroll. My research project has already shown incredible potential to uncover novel molecular therapeutic targets for the treatment of advanced prostate cancer. As a promising young surgeon-scientist, I was awarded the Department of Defense grant to interrogate the distinct ability of cancer cells to upregulate their stress response pathways upon oncogenic stress, chemotherapy and radiotherapy in order to evade cell death. I delineated the mechanisms underlying stress response pathways, in particular the unfolded protein response (UPR) and define their role in prostate tumorigenesis using genetic mouse models as well as in patient derived xenografts model of metastatic prostate cancer. My main research program was recently published in a high impact publication in Science Translational Medicine and resulted in a patent on the use of biomarker PTEN loss and high phospho eIF2α to identify lethal prostate cancer who may benefit from anti-eIF2α therapy. In 2016, I received the PCF young investigator award and the AUA Rising Star in Research award to develop patient derived xenograft (PDX) models to evaluate novel therapies for patients with neuroendocrine metastatic prostate cancer. In 2020, I received the 1 million-dollar PCF Challenge Grant to bring novel therapeutics for metastatic prostate cancer. I had published more than 50 journal articles and 4 book chapters. In addition to basic science, my clinical interest focuses on early detection of prostate cancer using advance imaging (PSMA PET/SPECT), novel biomarkers and MRI fusion biopsy in early diagnosis and treatment of prostate cancer. In 2019, I was appointed Benioff-Goldberg Endowed Professorship in Cancer Biology and the recipient of the William R. Smart M.D Distinguished Teaching Award.

Education

University of California, Berkeley, BA, 06/1999, Molecular Cell Biology/Cell and Developmental Biology (Graduated with Honor)
Boston University School of Medicine, MD, PhD, 06/2007
University of California, Davis, 06/2013, Residency in General Surgery, Residency in Urologic Surgery
University of California, San Francisco, 06/2015, Society of Urologic Oncology Fellowship

Honors & Awards

  • 2011
    International Volunteer in Urology (IVU) resident scholar
  • 2011
    Third Place in Clinical Research Competition at 37th annual Northern California Urology Resident Seminar
  • 2013
    First Place in Basic Science Research Competition at 39th annual Northern California Urology Resident Seminar
  • 2016
    Prostate Cancer Foundation Young Investigator Award 2016
  • 2017
    AUA Rising Stars in Urology Research Awards
  • 2018
    The Cancer League Young Investigator
  • 2019
    University of California, Davis Department of Urology Visiting Professorship
  • 2019
    Keynote Speaker Boston University School of Medicine MD-PhD program 2019 retreat
  • 2019
    Goldberg-Benioff Endowed Professorship in Cancer Biology
  • 2019
    William R. Smart M.D Distinguished Teaching Award

Selected Publications

  1. Balakrishnan AS, Nguyen HG, Shinohara K, Carroll PR, Odisho AY. Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy. Urol Oncol. 2022 Jul 12.  View on PubMed
  2. Greenberg SA, Cowan JE, Lonergan PE, Washington SL, Nguyen HG, Zagoria RJ, Carroll PR. The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. Prostate Cancer Prostatic Dis. 2022 02; 25(2):344-350.  View on PubMed
  3. Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100941.  View on PubMed
  4. Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Oncogene. 2022 03; 41(11):1536-1549.  View on PubMed
  5. Velarde N, Westphalen AC, Nguyen HG, Neuhaus J, Shinohara K, Simko JP, Larson PE, Magudia K. US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy. Abdom Radiol (NY). 2022 03; 47(3):1133-1141.  View on PubMed
  6. Chappidi MR, Bell A, Cowan JE, Greenberg SA, Lonergan PE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2022 05; 207(5):1001-1009.  View on PubMed
  7. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Nov 01; 7(11):1635-1642.  View on PubMed
  8. Xu Y, Huangyang P, Wang Y, Xue L, Devericks E, Nguyen HG, Yu X, Oses-Prieto JA, Burlingame AL, Miglani S, Goodarzi H, Ruggero D. ERα is an RNA-binding protein sustaining tumor cell survival and drug resistance. Cell. 2021 09 30; 184(20):5215-5229.e17.  View on PubMed
  9. Lonergan PE, Cowan JE, Washington SL, Greenberg SA, Nguyen HG, Carroll PR. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate. 2021 09; 81(13):1009-1017.  View on PubMed
  10. de la Calle CM, Shee K, Chu CE, Cowan JE, Nguyen HG, Carroll PR. Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. Urology. 2021 09; 155:91-95.  View on PubMed
  11. Greenberg SA, Washington SL, Lonergan PE, Cowan JE, Baskin AS, Nguyen HG, Odisho AY, Simko JP, Carroll PR. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. J Urol. 2021 09; 206(3):706-714.  View on PubMed
  12. Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 12; 204(6):1222-1228.  View on PubMed
  13. Washington SL, Cowan JE, Herlemann A, Zuniga KB, Masic S, Nguyen HG, Carroll PR. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. Prostate. 2021 02; 81(2):102-108.  View on PubMed
  14. Fasulo V, Cowan JE, Maggi M, Washington SL, Nguyen HG, Shinohara K, Lazzeri M, Casale P, Carroll PR. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. Eur Urol Oncol. 2022 02; 5(1):61-69.  View on PubMed
  15. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Reply by Authors. J Urol. 2020 12; 204(6):1221.  View on PubMed
  16. de la Calle CM, Fasulo V, Cowan JE, Lonergan PE, Maggi M, Gadzinski AJ, Yeung RA, Saita A, Cooperberg MR, Shinohara K, Carroll PR, Nguyen HG. Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. J Urol. 2021 02; 205(2):452-460.  View on PubMed
  17. Herlemann A, Overland MR, Washington SL, Cowan JE, Westphalen AC, Carroll PR, Nguyen HG, Shinohara K, Cooperberg MR. How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound? Eur Urol Focus. 2021 Nov; 7(6):1268-1273.  View on PubMed
  18. Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM. The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. Bioorg Med Chem. 2020 10 15; 28(20):115712.  View on PubMed
  19. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 12; 204(6):1216-1221.  View on PubMed
  20. Washington SL, Baskin AS, Ameli N, Nguyen HG, Westphalen AC, Shinohara K, Carroll PR. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. AJR Am J Roentgenol. 2020 03; 214(3):574-578.  View on PubMed

Go to UCSF Profiles, powered by CTSI